INTERNATIONAL PATENT: WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD., 威尚（上海）生物医药有限公司 FILES APPLICATION FOR "USE OF QUINAZOLINE COMPOUND AND THIRD-GENERATION EGFR INHIBITOR IN COMBINED DRUG FOR TREATING NON-SMALL CELL LUNG CANCER"

GENEVA, Sept. 8 -- WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (Room E8, 3rd Floor, Building 6, No. 4299, Jindu RoadMinhang District, Shanghai 201100), 威尚（上海）生物医药有限公司 (中国上海市闵行区金都路4299号6幢3楼E8室) filed a patent application (PCT/CN2025/072184) for "USE OF QUINAZOLINE COMPOUND AND THIRD-GENERATION EGFR INHIBITOR IN COMBINED DRUG FOR TREATING NON-SMALL CELL LUNG CANCER" on Jan 14, 2025. With publication no. WO/2025/180111, the details related to the patent application was published on Sep 04, 2025.

Notably, the patent application was submitt...